The arginase inhibitor N&#969;-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.

Ng, King Pan; Manjeri, Aditi; Lee, Lin Ming; Chan, Zhu En; Tan, Chin Yee; Tan, Qiancheng Darren; Majeed, A'Qilah; Lee, Kian Leong; Chuah, Charles; Suda, Toshio; Ong, S Tiong

The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.

Ng, King Pan; Manjeri, Aditi; Lee, Lin Ming; Chan, Zhu En; Tan, Chin Yee; Tan, Qiancheng Darren; Majeed, A'Qilah; Lee, Kian Leong; Chuah, Charles; Suda, Toshio; Ong, S Tiong.

Afiliación

Ng KP; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Manjeri A; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Lee LM; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Chan ZE; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Tan CY; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Tan QD; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Majeed A; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Lee KL; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Chuah C; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Suda T; Cancer and Stem Cell Biology Signature Research Program, Duke-NUS Medical School, Singapore, Singapore.
Ong ST; Department of Haematology, Singapore General Hospital, Singapore, Singapore.

PLoS One ; 13(10): e0205254, 2018.

Article en En | MEDLINE | ID: mdl-30307989

Asunto(s)

Antineoplásicos/farmacología; Apoptosis/efectos de los fármacos; Arginasa/antagonistas & inhibidores; Arginina/análogos & derivados; Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico; Antineoplásicos/uso terapéutico; Arginasa/genética; Arginasa/metabolismo; Arginina/farmacología; Arginina/uso terapéutico; Sistemas CRISPR-Cas/genética; Ciclo Celular/efectos de los fármacos; Línea Celular Tumoral; Proliferación Celular/efectos de los fármacos; Ensayos de Selección de Medicamentos Antitumorales; Pruebas de Enzimas; Estudios de Factibilidad; Técnicas de Inactivación de Genes; Humanos; Leucemia Mielógena Crónica BCR-ABL Positiva/patología; Cultivo Primario de Células; ARN Interferente Pequeño/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Arginasa / Arginina / Leucemia Mielógena Crónica BCR-ABL Positiva / Apoptosis / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Singapur

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google